SAGE Journals
Browse
Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2.pdf (1.19 MB)

Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 - Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market

Download (1.19 MB)
journal contribution
posted on 2018-01-10, 12:00 authored by Peter A. Patriarca, R. Michael Van Auken, Scott A. Kebschull

Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 for Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market by Peter A. Patriarca, R. Michael Van Auken, and Scott A. Kebschull in Therapeutic Innovation & Regulatory Science

History

Usage metrics

    Therapeutic Innovation & Regulatory Science

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC